title: Patient-reported impact of chronic urticaria compared with psoriasis in theUnited States.
abstract: OBJECTIVE
  Data are lacking on the burden of chronic idiopathic urticaria (CIU) versus other dermatologic conditions. This analysis compared the burden of chronic urticaria (CU, proxy for CIU) with psoriasis.
  
  
  METHODS
  Data from CU (N = 747) and psoriasis patients (N = 5107) came from 2010 to 2012 US National Health and Wellness Surveys. Outcomes included SF-12v2/SF-36v2 mental and physical component summary scores (MCS and PCS, respectively) and other health/activity-related measures.
  
  
  RESULTS
  MCS score was 44.7 for CU, and 48.2, 44.7 and 44.3 for mild/moderate/severe psoriasis, respectively (US norm = 50). PCS score was 43.8 for CU, and 46.5, 44.1 and 40.3 for mild/moderate/severe psoriasis. Health utility score was 0.67 for CU, and 0.72, 0.67 and 0.65 for mild/moderate/severe psoriasis. More CU patients reported depression (39%), anxiety (42%) and sleep difficulties (50%) than psoriasis patients (any severity). Overall work impairment was 29% for CU, and 19%, 26% and 31% for mild/moderate/severe psoriasis. Activities impairment was 39% for CU, and 28%, 37% and 43% for mild/moderate/severe psoriasis. CU and psoriasis patients had frequent healthcare visits.
  
  
  CONCLUSIONS
  Patients with CU had impaired mental/physical health and work/non-work activities, similar to moderate-to-severe psoriasis patients. Results suggest that better disease management of CU is needed. This analysis should also reflect the significant burden of CIU.
authors: a Novartis Pharmaceutical Corporation , East Hanover , NJ , USA.
authors: Meryl H
authors: MH
authors: Mendelson
authors: b Department of Medicine , University of Cincinnati , Cincinnati , OH , USA.
authors: Jonathan A
authors: JA
authors: Bernstein
authors: a Novartis Pharmaceutical Corporation , East Hanover , NJ , USA.
authors: Susan
authors: S
authors: Gabriel
authors: c Global HEOR, Novartis Pharma AG , Basel , Switzerland.
authors: Maria-Magdalena
authors: MM
authors: Balp
authors: a Novartis Pharmaceutical Corporation , East Hanover , NJ , USA.
authors: Haijun
authors: H
authors: Tian
authors: d Health Economics, Kantar Health , Horsham , PA , USA.
authors: Jeffrey
authors: J
authors: Vietri
authors: e Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York , NY , USA.
authors: Mark
authors: M
authors: Lebwohl
mesh_terms: D000328:Adult; D000368:Aged; D001007:Anxiety / Q000209:etiology; D002908:Chronic Disease; D003430:Cross-Sectional Studies; D003863:Depression / Q000209:etiology; D005260:Female; D006306:Health Surveys; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications / Q000473:pathology*; D011788:Quality of Life; D012189:Retrospective Studies; D057566:Self Report; D012720:Severity of Illness Index; D012893:Sleep Wake Disorders / Q000209:etiology; D014481:United States; D014581:Urticaria / Q000150:complications / Q000473:pathology*
keywords: Chronic hives; burden; health-related quality of life; skin disorders